Ahead of China’s annual legislative meetings – typically a window into Beijing’s top-level policy agenda – this is the eighth entry in a series examining the complex economic recalibration driving China’s growth philosophy and its wide-ranging implications for local governments, financial investors and private enterprises.
Investors are watching Beijing’s annual “two sessions” this week for signs that the country will address drug pricing and shore up its drug payment system, as a new form of…
